Synairgen shares climb after positive news from trials

0 mins. to read
Synairgen shares climb after positive news from trials

Respiratory drug discovery specialist Synairgen (LON:SNG) saw its shares climb by 7.29% to 15.82p (as at 13:30 BST) after the company announced positive developments from phase II trials for a antiviral treatment for chronic obstructive pulmonary disease.

Get the latest from Master Investor directly in your inbox – Sign-up HERE for FREE

Management said that the treatment had been well tolerated during the tests and had shown statistically significant increases in antiviral biomarkers in patients. Testing is scheduled to continue over the winter with the company aiming to enroll 80 subjects to check various endpoints.




Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *


Get real investment insights from some of the best minds in the business - with our free Master Investor Magazine.